Clinical trials
Mutation clinical trials
Below are recruiting mutation clinical trials, each written for real people, not researchers. We’re tracking 739 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05584722Recruiting
Study risk and resilience in pulmonary arterial hypertension
This study looks at how people with pulmonary arterial hypertension (PAH) and certain genetic risks cope and how their bodies respond over time. It may help researchers understand factors linked to better or worse outcomes, and how different people manage the condition.
Nashville, TennesseeAges 15–80 - NCT05598528Recruiting
Study why some lung cancers don’t respond to EGFR pills
This study looks at why certain EGFR-positive advanced lung cancers resist third-generation EGFR tablet treatment given as the first treatment. Your body samples and scan results help researchers understand the resistance, which may guide better future care.
Changsha, HunanAges 18 years+ - NCT05639413Recruiting
Study of biology in people with BRAF V600E metastatic colon cancer
This study follows people with BRAF V600E–positive metastatic colorectal (colon) cancer to better understand how the cancer’s biology changes over time. It may help researchers learn which features to watch and how this cancer behaves after initial treatment.
AvignonAges 18 years+ - NCT05691036Recruiting
Studying bile acid levels and genes in pregnancy itching
This study looks at bile acid levels and possible genetic changes in people with persistent pregnancy itching. The goal is to better understand the cause of intrahepatic cholestasis of pregnancy and related pregnancy outcomes.
Chandigarh, ChandigarhAges 21–45 - NCT05706779RecruitingPhase 2
Encorafenib plus cetuximab before surgery for BRAF-mutated colon cancer
This trial tests whether giving encorafenib and cetuximab before surgery can shrink or control BRAF-mutated colon or upper rectal cancer and make surgery more effective. It also checks whether this approach is safe and helps patients do better overall.
ParisAges 18 years+ - NCT05768490RecruitingPhase 3
Radiation plus targeted pills for EGFR lung cancer brain spots
This Phase 3 study tests whether giving brain radiation early or later, along with almonertinib (a targeted pill), works better for people with EGFR-mutated non-small cell lung cancer that has a small number of brain metastases. It aims to control brain disease while checking safety and effectiveness in a carefully selected group.
Guangdong, GuangzhouAges 18–75 - NCT05848271Recruiting
Natural history study for people with HPDL gene changes
This study follows people who have an HPDL gene change to better understand how symptoms and health progress over time. It may help clinicians learn more about the condition and plan future treatments.
San Diego, CaliforniaAges Any age - NCT05868629Recruiting
Test of two targeted drugs for tumors with BRAF V600E
This trial tests dabrafenib plus trametinib in people whose solid tumors have a BRAF V600E mutation that cannot be fully removed by surgery or has spread. It looks at whether these targeted medicines can shrink tumors and control the disease.
Torrance, CaliforniaAges 1–100 - NCT05906953RecruitingPhase 1/Phase 2
HG004 gene therapy for RPE65 vision loss
This Phase 1/2 trial tests the safety and early effectiveness of HG004 (a gene therapy) in people with Leber congenital amaurosis caused by RPE65 gene changes. It aims to see whether treating the eye can improve or stabilize vision-related measures while monitoring side effects.
Sacramento, CaliforniaAges 6–50 - NCT05948813RecruitingPhase 2
TY-9591 for EGFR-mutant lung cancer spread to the brain
This phase 2 trial studies TY-9591 in people with advanced non-small cell lung cancer (NSCLC) that has spread to the brain and has specific EGFR mutations. It aims to see whether the medicine can control the cancer in the brain and the rest of the body, without needing immediate brain radiation.
Beijing, Beijing MunicipalityAges 18–80 - NCT05967689RecruitingPhase 2
Zipalertinib for lung cancer with EGFR exon 20 mutations
This Phase 2 trial tests zipalertinib (a targeted pill) in people with advanced non-small cell lung cancer (NSCLC) that has specific EGFR mutations, especially “exon 20 insertions.” It may help shrink tumors or slow cancer growth, including in some people with brain metastases.
Birmingham, AlabamaAges 18 years+ - NCT05970302RecruitingPhase 2
XELOX, bevacizumab, and immunotherapy for metastatic colon cancer
This Phase 2 trial studies a combination treatment (XELOX plus bevacizumab plus an immunotherapy drug) for people with metastatic colon cancer that has certain lab features (MSS/pMMR and RAS-mutated). It aims to see how well the treatment works as a first treatment when the cancer cannot be removed with surgery.
BeijingAges 18 years+ - NCT05983159RecruitingPhase 2
Targeted therapy for slow-flow or fast-flow vascular malformations
This trial tests two targeted medicines for people with certain types of vascular malformations (abnormal blood vessels). If you have a slow-flow malformation, you may receive alpelisib; if you have a fast-flow malformation, you may receive mirdametinib. Genetic testing is needed to see if your malformation has a specific change that these drugs target.
Parkville, VictoriaAges 2 years+ - NCT05983991Recruiting
Study of GATA2 gene changes over time
This study looks at how GATA2 gene changes affect your blood cells over time. It is for people of any age who have a GATA2 mutation they were born with, and it does not test a new drug—just collects information and samples during regular checkups.
AngersAges Any age - NCT06001788RecruitingPhase 1
Ziftomenib for relapsed or refractory acute myeloid leukemia
This trial tests a new drug combination called ziftomenib for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. Researchers will check how safe it is and what side effects happen.
Gilbert, ArizonaAges 18 years+ - NCT06008392Recruiting
Mayo Clinic cancer genetics research study
This study collects blood, saliva, tumor tissue, or hair samples to look for inherited and tumor-related gene changes that may explain your cancer, guide prevention, or help find better treatments. You can join if you are a Mayo Clinic patient with cancer and your doctor has ordered genetic testing.
Scottsdale, ArizonaAges 18 years+ - NCT06022003RecruitingPhase 2
Azacitidine plus gilteritinib for FLT3-mutated AML
This trial tests whether adding an oral chemotherapy pill (azacitidine) to the targeted drug gilteritinib helps people whose FLT3-mutated AML came back or didn't respond after their first treatment. The goal is to see if the combination is more effective than gilteritinib alone.
AmiensAges 18 years+ - NCT06041776RecruitingPhase 3
Befotertinib after surgery for early-stage lung cancer with EGFR mutation
This trial tests if a targeted therapy pill (befotertinib) can lower the chance of cancer coming back after surgery for non-small cell lung cancer that has a specific EGFR mutation. You may be eligible if your tumor was completely removed and you have stage IB to IIIB disease.
BeijingAges 18 years+ - NCT06043817RecruitingPhase 1/Phase 2
Study of STX-721 for advanced lung cancer with EGFR or HER2 changes
This trial tests a new drug, STX-721, for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR or HER2 exon 20 insertion). The study aims to see if the drug is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT06053099Recruiting
Study of osimertinib after surgery for EGFR-mutated lung cancer
This trial collects data from people with early-stage lung cancer that has a common EGFR mutation. After complete surgical removal of the tumor, participants take osimertinib for 3 years and are followed regularly to see how well the treatment works and why resistance might develop.
AngersAges 18 years+ - NCT06088030RecruitingPhase 2
Arsenic trioxide plus chemo for p53-mutated childhood cancer
This trial tests if adding arsenic trioxide to standard chemotherapy can help children with cancers that have a certain p53 gene change. The goal is to see if the drug can reactivate the broken p53 protein to fight the tumor.
Guangzhou, GuangdongAges Up to 18 years - NCT06192849RecruitingPhase 2
Furmonertinib after surgery for EGFR 20 insertion lung cancer
This trial tests a targeted pill (furmonertinib) to prevent your lung cancer from coming back after surgery. It is for people with a certain genetic change in their tumor (EGFR exon 20 insertion) and stage IB, II, or IIIA disease.
Chengdu, SichuanAges 18 years+ - NCT06201234RecruitingPhase 2
Adding elacestrant to olaparib for advanced HR+/HER2- breast cancer
This trial tests if adding a new oral medicine (elacestrant) to a standard PARP inhibitor (olaparib) works better for people with advanced or metastatic HR+/HER2- breast cancer who have a BRCA1 or BRCA2 gene mutation. The goal is to see if the combination can help control the cancer longer.
Stuttgart, Baden-WurttembergAges 18 years+ - NCT06218810RecruitingPhase 2
Combination therapy for advanced MSS, RAS-mutated colorectal cancer
This trial tests a new combination of three medicines for people with a certain type of advanced colorectal cancer that has not been treated before. It aims to see if adding an immunotherapy drug (Cadonilimab) to standard chemotherapy and a targeted therapy (Bevacizumab) can help shrink tumors and delay disease progression.
ShanghaiAges 18–75
Hear when a new Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for mutation?
- Yes. Clin2 currently lists 739 recruiting mutation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a mutation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a mutation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.